跳至主要内容
临床试验/NCT06232161
NCT06232161进行中(未招募)不适用

Retrospective,2-Year Post-Trial Follow-up Study of Sustained and Rebound Effect of Red-light Therapy for Myopia in Ningbo.

Beijing Airdoc Technology Co., Ltd.1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2020年5月13日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
50
试验地点
1
主要终点
Change of axial length (mm) with the measurement of device named by IntraOcular Lens Master(IOLmaster 500)

研究概览

简要总结

To evaluate the long-term efficacy and safety of red-light therapy for myopia control over 2 years, and the potential rebound effect after treatment cessation.

The Chinese myopic children who originally completed the one-year randomised controlled trial in the previous study were enrolled. Children continued or started to daily usage of red-light therapy were defined as the RL group, while those who stopped using red-light therapy and switched to single-vision spectacles (SVS) as well as those who continued to keep single-vision spectacles in the second year were both regarded as the SVS group. Red-light therapy was provided by an at-home desktop light device emitting red-light of 650 nm and was administered for 3 min at a time, twice a day. Changes in axial length (AL) and cycloplegic spherical equivalence refraction (SER) are to be measured and compared as well as the adverse effects including the rebound effect.

Red-light therapy has emerged as a novel myopia control treatment modality recently. A 12-month randomised controlled trial (RCT) conducted by our research team was thought to be earlier to evaluate the treatment of myopic children using red-light therapy. The trial demonstrated that PBM therapy was effective on myopia control, reducing axial elongation and spherical equivalence refraction (SER) progression 103% and 127% compared with single vision spectacle (SVS) over a 12-month period, respectively. The promising efficacy of red-light therapy has been further confirmed in other studies. In addition, satisfactory user acceptability and no unrecovered functional and structural damages were observed.

Myopia generally progresses throughout childhood and hence a study duration of 1 year is not sufficient to widely adopt the red-light therapy as a treatment strategy for myopia control. The sustainability of treatment efficacy, rebound phenomenon upon cessation of treatment, and potential risks and adverse effects in myopic children with longer-term PBM therapy, remain to be fully elucidated.

Thus, the aims of this post-trial follow-up study were to invite the participants to come back for a 24-month visit and to investigate the long-term efficacy and safety of continued red-light therapy as well as the potential rebound effect following red-light treatment cessation.

详细描述

Interventions and visits All spectacle lenses were made for single focus with full correction for each subject as the first intervention throughout the whole procedure for both groups. PBM therapy was performed with a low-intensity laser (LD-A, Jilin LD Optoelectronics Technology, Jilin, China) with an irradiance of 0.35 ± 0.02 mW/cm2, a wavelength of 650 nm ± 10 nm, and illumination of approximately 400 lux on average at the first 12 month. At the second 12 months, non-randomized cohorts continued according to the willing to use the device from both groups. Once decided, those usage would be followed up for another 12 months for tracking the change of axial length as well as the change of refractive error. All the adverse effects and any harms are encouraged to report during the next 12 months' study.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
9 Years 至 13 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of myopia;
  • Ages of 9~13 years old;
  • Must be with best corrected visual acuity ≥20/25 (decimal record);
  • Must be the subject in the previous study of 12-month red-light therapy of myopia;

排除标准

  • Clinical diagnosis of glaucoma or retinal lesions;
  • Clinical diagnosis of optic media lesions (e.g., central thick corneal scars, cataract);
  • Clinical diagnosis of optic nerve dysfunction;
  • Clinical diagnosis of amblyopia;
  • Must be eligible for follow-up.

结局指标

主要结局

Change of axial length (mm) with the measurement of device named by IntraOcular Lens Master(IOLmaster 500)

时间窗: 12-month

The change of axial length (mm) from the 24 months and 12 months from the baseline for each subject; The right eye were considered for the comparison between groups. The change value is recorded of the average from 5 values at the same follow-up

次要结局

  • Change of refractive error (D) with cycloplegic refraction with the same autorefractor(12-month)

研究者

申办方类型
Industry
责任方
Principal Investigator
主要研究者

Qiu Kaikai

Myopia control officer

Ningbo Eye Hospital

研究点 (1)

Loading locations...

相似试验